Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. “Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”. . Most recently the FDA awarded MMJ International Holdings ? Orphan Drug Designation?

DEA 51

DEA Clinical Trials THC Research and Development 51

NewsMunchies

NOVEMBER 12, 2021

Psilocybin is the active ingredient found in magic mushrooms and research suggests it has the potential to treat various mental illnesses and is safer than pharmaceutical drugs and alcohol, which can be habit-forming. We know such categorization is baseless and false. Rate this blog post.

Clinical Trials 90

Clinical Trials Therapy Decriminalization DEA 90

Cannabis Law Report

JULY 1, 2021

Mason Marks: The project’s goal is to promote safety, innovation, equity, and accessibility in emerging psychedelics industries. We will also translate existing clinical research, making it more accessible to courts, lawmakers, federal agencies, and the public. Chloe Reichel: Can you describe the primary goals of POPLAR?

Law 81

Law Research and Development Therapy DEA 81

Cannabis Law Report

DECEMBER 15, 2021

The importation of the naturally derived psilocybin into California was completed after the Company’s supply partner Mycrodose Therapeutics was granted an import license from the United States Drug Enforcement Administration (DEA). “Having a supply partner that gives us access to the rapidly growing U.S.

Supply Chain 52

Supply Chain Research and Development DEA Pharmaceutical 52

MedicalJane

JUNE 29, 2018

Marketing unapproved products, with uncertain dosages and formulations can keep patients from accessing appropriate, recognized therapies to treat serious and even fatal diseases.”. The Next Move Is On The DEA. Epidiolex’s launch is in the hands of the DEA. subsidiary of GW Pharmaceuticals.

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Burns Levinson (Cannabusiness advisory)

OCTOBER 3, 2018

This marks the first time in history that the DEA has removed any type of cannabis from Schedule I, and clears the way for the sale of the first non-synthetic, cannabis-derived medicine to win federal approval. According to the DEA order, because the drug was recently approved by the FDA, it is now considered to have an accepted medical use.

CBD 40

CBD DEA Epilepsy Pharmaceutical 40

Cannabis Law Report

JULY 9, 2021

Further, numerous private companies have begun to research psychedelic therapy and develop new pharmaceutical compounds derived from psychedelic substances. Right to Try laws permit patients with serious or life-threatening diseases to access drugs that do not yet have government approval. Drug Enforcement Agency (“DEA”).

Law 81

Law Therapy Clinical Trials Research and Development 81

Sensi Seeds

NOVEMBER 28, 2018

The confusion is compounded by the fact another CBD company, GW Pharmaceuticals, the British Biotech and marijuana grower, managed to secure approval from the U.S. CBD Regulation is Needed.

CBD 71

CBD Seed-To-Sale Food Research and Development 71

Cannabis Info

MARCH 21, 2019

have legalized cannabis for either recreational or medical uses, allowing companies to thrive, the plant is still illegal on a Federal level – classified as a Schedule I drug by the DEA. Moreover, most people usually don’t have access to the resources needed to make an informed assessment of a company. While multiple states in the U.S.

Marijuana 59

Marijuana Pharmaceutical Hash Cannabinoids 59

Cannabis Law Report

APRIL 21, 2022

Publication of this process establishes “prior art,” contributing to MAPS’ patient access strategy by making intellectual property public . Promising clinical trial results have generated much interest in studying MDMA as a catalyst to therapy for PTSD and related conditions — and an increased demand for pharmaceutical-grade MDMA.

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

AUGUST 12, 2022

Obtaining DEA License to Grow Psilocybin Mushrooms. As research on the therapeutic potential of certain psychedelics expands, there are looming questions about where the pharmaceutical industry might fit in—and the possible corporatization and consolidation that could come with that. Here are some psychedelics panel options: .

Research and Development 52

Research and Development Topical Events Policy 52

Cannabis Info

OCTOBER 4, 2019

He went on to talk on the calls for of the pharmaceutical area directing his work in recent times. Demetrix is licensed by the DEA to do analysis with pure cannabinoid compounds. The answer is you start with the harder-to-access stuff ,” Demetrix’s CEO Jeff Ubersax instructed Cannabis Now.

Cannabinoids 45

Cannabinoids THC Wellness and Beauty Research and Development 45

Medicinal Genomics

NOVEMBER 12, 2024

As a result, labs that have received a state license to test either medical or recreational cannabis have historically been denied a DEA Schedule I license to test hemp under the 2018 Farm Bill. However, this may change with rescheduling that is going to be revisited on Dec 2, 2024.

Compliance 52

Compliance Compliance Data Agriculture 52

Cannabis Law Report

MAY 17, 2019

Seq (1970) and Drug Enforcement Administration’s (“DEA”) clutches, 2019 hemp production and sales exploded. A wildly popular nutritional supplement and food additive, oil based hemp derived products like CBD racked up $1.1 Farm Bill’s Impact and Rise of the FDA. Beyond removing plant cannabis sativa L. Budgeted at $6.1

Food 10

Food DEA Hemp CBD 10

Cannabis Law Report

JULY 30, 2019

Like others, Dr. Beasley is forced by default to expand her knowledge base through scientific facts that warrant closer inspection and through accessible existing research, with few current cannabis case studies. Cannabis is not a “gateway” drug, according to the ASA and the DEA’s own statements cited in the August 2016 U.S.

Marijuana 45

Marijuana Patients Research and Development Programs 45

Cannabis Law Report

OCTOBER 14, 2021

The study, conducted independently by Colorado State University researchers and published in the peer-reviewed, open-access scientific journal Pharmaceuticals , explored the pharmacokinetics of edible THC. Well, it doesn’t get more real-world than actual consumer products tested with actual consumers,” said Singer.

THC 40

THC Edibles Cannabinoids Data 40

SpeedWeed

DECEMBER 28, 2018

Marinol (synthetic THC) has been available by prescription since 1986, and other synthetic cannabinoid drugs are in the works, but Epidiolex is the first plant-derived pharmaceutical to reach the US market. Bummer: Patients Are Still Struggling for Cannabis Access.

Pharmaceutical 40

Pharmaceutical Research and Development Legalization CBD 40

The Cannigma

JUNE 14, 2021

All that is about to change, thanks to a change at the DEA , which cultivators and industry experts say will be monumental for cannabis research, medical marijuana patients, and potentially the broader legal status of the plant itself. “We BRC) told The Cannigma this week. Junk’ cannabis ‘ill-suited for clinical trials’. Shutterstock).

DEA 133

DEA Research and Development Clinical Trials Pharmaceutical 133

Canna Law Blog

NOVEMBER 27, 2021

So according to the DEA, its abuse potential is high and it has no medical use. Also, according to the DEA, “the history of human experience probably goes back several hundred years since DMT usage is associated with a number of religious practices and rituals.”

Therapy 98

Therapy Clinical Trials DEA Microdosing 98

Canna Law Blog

JULY 25, 2020

Due to its high English speaking population, its significant diaspora in the United States, and its strong pharmaceutical industry that is already tied to the United States, the Philippines is an attractive cannabis participant, both as part of the supply chain and as a potential sales market. FDA and DEA.

Supply Chain 98

Supply Chain DEA Legislation Hemp 98

Project CBD

AUGUST 23, 2023

Earlier this year, the Food & Drug Administration disclosed that it would not regulate non-pharmaceutical CBD products, thereby putting the onus on Congress to devise an appropriate regulatory framework for cannabidiol and other hemp-derived cannabinoids. Caffeine can also be found in pharmaceutical 33 and non-pharmaceutical products.)

Cannabinoids 143

Cannabinoids Hemp THC Safety 143

Canna Law Blog

NOVEMBER 16, 2021

The enforcement role moves from DEA to ATF. When it comes to enforcing federal cannabis regulations, the Drug Enforcement Administration (“DEA”) is out and the Bureau of Alcohol, Tobacco, Firearms, and Explosives (“ATF”) is in (in addition to TTB as the primary overseer). . ” SBA fairness.

DEA 98

DEA Business Banking Food 98

Canna Law Blog

MARCH 4, 2020

People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs. “ Off-label use ” (which is extremely common) is: the use of pharmaceutical drugs for an unapproved indication or in an unapproved age group, dosage, or route of administration.

Legalization 59

Legalization Therapy Chronic Pain DEA 59

Veriheal

AUGUST 31, 2020

Essay Summary: Although doctors’ offices are full of pamphlets and flyers about mainstream pharmaceuticals in both English and Spanish, there is a lack of information for Hispanic patients seeking relief with cannabis and CBD. . Essay: “Combining Social Sciences and Pharmacology to Make a Positive Social Impact in Cannabis” .

Research and Development 119

Research and Development Education Agriculture Patients 119

SpeedWeed

MARCH 25, 2021

Dr. Sisley eventually sued the DEA to demand that they allow more institutions to grow research weed, but even with the intervention of a federal court , the DEA has yet to approve additional growers. . Is it any wonder why millions prefer cannabis over deadly pharmaceuticals and other harmful substances?

DEA 52

DEA Clinical Trials THC Pharmaceutical 52

SpeedWeed

AUGUST 19, 2021

In recent months, a synthetic compound derived from hemp called THC-O acetate—often referred to simply as THC-O (pronounced “THC oh”)—has quickly gained popularity among Americans who don’t have access to legal cannabis. . THC-O products are increasingly popular in states where consumers don’t have access to legal cannabis.

THC 40

THC Hemp Extraction Vaping 40

SpeedWeed

MARCH 18, 2021

Wasn’t the DEA going to let others grow research-grade cannabis? Veterans groups advocating for more access to cannabis, meanwhile, are applauding the newly-published study. Is it any wonder why millions prefer cannabis over deadly pharmaceuticals and other harmful substances? It tested at only 9% THC.

Clinical Trials 40

Clinical Trials THC Strains Cannabis 40

Canna Law Blog

AUGUST 31, 2023

This all looks pretty good right now, but the Drug Enforcement Administration (DEA) and ultimately the Attorney General (AG) have final say on whether to schedule or reschedule marijuana following the HHS recommendation. In any case, the DEA Administrator reports to the AG (through the Deputy AG). The AG could then reschedule.

DEA 128

DEA Marijuana Banking Research and Development 128

The Cannigma

SEPTEMBER 12, 2021

This contradiction, combined with a problematic regulatory framework that limits access to THC products in many states, has created a booming market for d-8 and d-10. Depending on the state you’re in, THC products may be legally accessible to any adult, and other states restrict access to medical patients only. THC vs CBD.

THC 98

THC Research and Development Cannabinoids CBD 98

NORML

SEPTEMBER 20, 2019

We also spoke with her attorneys, who explained why they believed the DEA broke the law by holding up long-promised medical marijuana research licenses. It’s been nearly three years since the DEA announced its revolutionary cultivator program. Dr. Sue Sisley. Later that night, everyone celebrated at a hotel bar.

DEA 234

DEA Research and Development Clinical Trials Patients 234

Cannabis Law Report

FEBRUARY 28, 2022

Importantly, control of psychedelics by a small number of companies may stifle innovation and reduce access to these therapies. 1669, 1670 (2021) (arguing that patents on psychedelics may limit research, innovation, and public access). Glenn Cohen, Psychedelic Therapy: A Roadmap for Wider Acceptance and Utilization , 27 NATURE MED.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Canna Law Blog

MARCH 5, 2025

But there’s a group of players who’ve been surprisingly quiet, despite potentially having the most to gain: DEA-registered bulk marijuana manufacturers. However, under current US law, DEA Registrants are missing out on a massive opportunity. This booming global market is one that DEA Registrants are unable to access.

DEA 68

DEA Research and Development Marijuana Pharmaceutical 68

Veriheal

NOVEMBER 7, 2024

The Drug Enforcement Administration (DEA) announced in August that a hearing regarding the reclassification decision will take place on December 2, 2024, before an administrative law judge. Then, the DEA will review the report and draft a final ruling, factoring in all relevant information submitted during the public comment period.

DEA 97

DEA Policy Chronic Pain Marijuana 97